Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.

× No keyword cloud information.

13 in total

1. Factors predicting Medicare national coverage: an empirical analysis.

Authors: James D Chambers; Stephen Morris; Peter J Neumann; Martin J Buxton
Journal: Med Care Date: 2012-03 Impact factor: 2.983

2. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.

Authors: P L Zinzani; E Pavone; S Storti; L Moretti; P P Fattori; L Guardigni; B Falini; M Gobbi; P Gentilini; V M Lauta; M Bendandi; F Gherlinzoni; M Magagnoli; S Venturi; E Aitini; M Tabanelli; G Leone; V Liso; S Tura
Journal: Blood Date: 1997-06-01 Impact factor: 22.113

3. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Authors: Arnold L Potosky; Jennifer L Malin; Benjamin Kim; Elizabeth A Chrischilles; Solomon B Makgoeng; Nadia Howlader; Jane C Weeks
Journal: J Natl Cancer Inst Date: 2011-06-13 Impact factor: 13.506

4. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.

Authors: Kelvin K W Chan; Eric Siu; Murray D Krahn; Kevin Imrie; Shabbir M H Alibhai
Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544

5. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

Authors: J K Doorduijn; B van der Holt; G W van Imhoff; K G van der Hem; M H H Kramer; M H J van Oers; G J Ossenkoppele; M R Schaafsma; L F Verdonck; G E G Verhoef; M M C Steijaert; I Buijt; C A Uyl-de Groot; M van Agthoven; A H Mulder; P Sonneveld
Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544

6. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.

Authors: R Pettengell; H Gurney; J A Radford; D P Deakin; R James; P M Wilkinson; K Kane; J Bentley; D Crowther
Journal: Blood Date: 1992-09-15 Impact factor: 22.113

7. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia.

Authors: J C Weeks; M R Tierney; M C Weinstein
Journal: N Engl J Med Date: 1991-07-11 Impact factor: 91.245

Review 8. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.

Authors: Julia Bohlius; Christine Herbst; Marcel Reiser; Guido Schwarzer; Andreas Engert
Journal: Cochrane Database Syst Rev Date: 2008-10-08

9. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

Authors: J M Vose; M Crump; H Lazarus; C Emmanouilides; D Schenkein; J Moore; S Frankel; I Flinn; W Lovelace; J Hackett; B C Liang
Journal: J Clin Oncol Date: 2003-02-01 Impact factor: 44.544

10. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.

Authors: Gary Lyman; Anjana Lalla; Richard Barron; Robert W Dubois
Journal: Curr Med Res Opin Date: 2009-02 Impact factor: 2.580

1 in total

Review 1. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.

Authors: Gisoo Barnes; Ashutosh Pathak; Lee Schwartzberg
Journal: Cancer Med Date: 2014-11-20 Impact factor: 4.452

1 in total